跳到正文
原文
STAT 主站· Adam Feuerstein·· 3 天前精选AI 评分75

赛拉思实验性血液癌症免疫疗法临床试验成功降低死亡风险

STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

AI 导读

赛拉思的实验性血液癌症免疫疗法galinpepimut-S在三期临床试验中将急性髓系白血病晚期患者的死亡风险降低了41%,达到主要研究终点。

推荐理由

临床试验结果显示某药显著降低急性髓系白血病患者的死亡风险,具有重要治疗意义。

正文

The unexpected result is good news for patients with acute myeloid leukemia

histopathology from patient with acute myeloid leukemia (AML)
Histopathology from patient with acute myeloid leukemia.CDC

By Adam Feuerstein

Nov. 17, 2026

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy. 

On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia (AML) — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said. 

In a column published in September, I predicted galinpepimut would fail to prolong survival in the Phase 3 study. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Senior Writer, Biotech

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

来源:STAT 主站 · statnews.com